The STAT3 inhibition, through the reversible decoy effect, combined with concurrent TLR9 activation seemed sufficient for the induction of the lymphoma differentiation to antigen-presenting phenotype, thereby ensuring therapeutic antitumor efficacy. Here, STAT3 is linked to lymphoma.